Shalini Cp Singh

US Patent:

20120264127, Oct 18, 2012

Filed:

Dec 30, 2010

Appl. No.:

13/518135

Inventors:

Shalini Singh - Tucson AZ, US
Hiro Nitta - Oro Valley AZ, US
Fabien Gaire - Stamberg, DE
Edmundo David Del Valle - Tucson AZ, US

International Classification:

C12Q 1/68
G01N 21/78

US Classification:

435 611, 435 617

Abstract:

The present invention provides compositions and methods for simultaneously detecting mutational status and gene copy number. In particular, the present invention provides simultaneous measurement of gene copy number and detection of the L858R and Exon 19 del mutations in a tissue sample.

US Patent:

20120141472, Jun 7, 2012

Filed:

May 28, 2010

Appl. No.:

13/322495

Inventors:

Shalini Singh - Tucson AZ, US
Fabien Gaire - Oro Valley AZ, US
James Ranger-Moore - Tucson AZ, US

International Classification:

A61K 39/395
A61K 31/5377
A61K 31/517
C12Q 1/68
G01N 21/64

US Classification:

4241331, 435 611, 4241721, 5142664, 5142345

Abstract:

Disclosed herein are methods of predicting prognosis of a neoplastic disease (such as lung cancer, for example NSCLC), including determining the IGF1R gene copy number in a biological sample from a patient having a neoplastic disease; wherein an increase in IGF1R copy number predicts a good prognosis of the neoplastic disease in the patient. Also disclosed herein are methods of scoring copy number of a gene of interest in a biological sample. The method includes identifying individual cells in the sample having highest number of signals for the gene of interest detected by in situ hybridization, counting the number of signals for the gene of interest in the identified individual cells and determining an average number of signals per cell.

US Patent:

20210063403, Mar 4, 2021

Filed:

Oct 21, 2020

Appl. No.:

16/949252

Inventors:

- Tucson AZ, US
Zhiming Liao - Livermore CA, US
Andrea Muranyi - Tucson AZ, US
Kandavel Shanmugam - Oro Valley AZ, US
Shalini Singh - Tucson AZ, US
Yifei Zhu - San Jose CA, US

International Classification:

G01N 33/574
C07K 16/22
C07K 16/30

Abstract:

The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

US Patent:

20200225237, Jul 16, 2020

Filed:

Mar 13, 2020

Appl. No.:

16/818809

Inventors:

- Tucson AZ, US
June F. Clements - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Hiro Nitta - Tucson AZ, US
Esteban Roberts - Tucson AZ, US
Crystal Schemp - Tucson AZ, US
Shalini Singh - Tucson AZ, US
Penny Towne - Tucson AZ, US

International Classification:

G01N 33/574
A61K 31/4545

Abstract:

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

US Patent:

20190269716, Sep 5, 2019

Filed:

May 14, 2019

Appl. No.:

16/412057

Inventors:

- Tucson AZ, US
- Pleasanton CA, US
- Berlin, DE
Andrea Muranyi - Tucson AZ, US
Ulrich-Peter Rohr - Pleasanton CA, US
Kandavel Shanmugam - Tucson AZ, US
Shalini Singh - Tucson AZ, US
Ulrike Stein - Berlin, DE

International Classification:

A61K 31/7072
A61P 35/04
C12Q 1/686
G01N 1/30
A61K 31/52
A61K 31/513
C12Q 1/6886
G01N 21/88

Abstract:

A combination of mismatch repair (MMR) and Metastasis Associated in Colon Cancer 1 (MACC1) gene expression status of the patient serve as a basis for risk stratification of early stage colon cancer patients. Patients with defective MMR (dMMR) status have improved survival and do not benefit from 5-fluorouracil (5-FU) therapies. In contrast, patients with a proficient MMR (pMMR) status have a higher risk of recurrence and worse survival. The pMMR patients are then further stratified on the basis of MACC1 gene expression. Patients with a pMMR status and a low MACC1 expression have a favorable prognosis similar to patients having a dMMR status, whereas patients having a pMMR status and high MACC1 expression have a less favorable prognosis.

US Patent:

20180196057, Jul 12, 2018

Filed:

Dec 21, 2017

Appl. No.:

15/851502

Inventors:

- Tucson AZ, US
- Pleasanton CA, US
Andrea Muranyi - Tucson AZ, US
Kandavel Shanmugam - Chandler AZ, US
Shalini Singh - Tucson AZ, US
Yifei Zhu - San Jose CA, US

International Classification:

G01N 33/574
C07K 16/22
C07K 16/30

Abstract:

The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

US Patent:

20170309021, Oct 26, 2017

Filed:

Jun 30, 2017

Appl. No.:

15/640412

Inventors:

- Tucson AZ, US
Ting Chen - Sunnyvale CA, US
Shalini Singh - Tucson AZ, US
Alisa Tubbs - Phoenix AZ, US

International Classification:

G06T 7/00
G06T 7/00
G06F 19/00

Abstract:

Described herein are methods for co-expression analysis of multiple markers in a tissue sample comprising: computing a heat map of marker expression for each of a plurality of single marker channel images, wherein each of the plurality of single marker channel images comprise a single marker; identifying one or more candidate regions of interest in each heat map of marker expression; computing overlay masks comprising the identified one or more candidate regions of interest from each heat map of marker expression; determining one or more co-localized regions of interest from the overlay masks; mapping the one or more co-localized regions of interest to a same coordinate position in each of the plurality of single marker channel images; and estimating a number of cells in at least one of the determined one or more co-localized regions of interest in each of the plurality of single marker channel images.

US Patent:

20170205416, Jul 20, 2017

Filed:

Mar 31, 2017

Appl. No.:

15/475668

Inventors:

- Tucson AZ, US
Hiro Nitta - Tucson AZ, US
Michael Barnes - Oro Valley AZ, US
Penny Towne - Tucson AZ, US
Shalini Singh - Tucson AZ, US
June F. Clements - Tucson AZ, US
Crystal Schemp - Tucson AZ, US
Esteban Roberts - Tucson AZ, US

International Classification:

G01N 33/574
A61K 31/4545

Abstract:

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.